IL315331A - A method of preventing age-related ocular degeneration by providing a drug entry mechanism into the eye - Google Patents

A method of preventing age-related ocular degeneration by providing a drug entry mechanism into the eye

Info

Publication number
IL315331A
IL315331A IL315331A IL31533124A IL315331A IL 315331 A IL315331 A IL 315331A IL 315331 A IL315331 A IL 315331A IL 31533124 A IL31533124 A IL 31533124A IL 315331 A IL315331 A IL 315331A
Authority
IL
Israel
Prior art keywords
administering
drug delivery
macular degeneration
related macular
ocular drug
Prior art date
Application number
IL315331A
Other languages
English (en)
Hebrew (he)
Inventor
Said Saim
Jay S Duker
Dario Paggiarino
Michelle Howard-Sparks
Original Assignee
Eyepoint Pharmaceuticals Inc
Said Saim
Jay S Duker
Dario Paggiarino
Howard Sparks Michelle
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eyepoint Pharmaceuticals Inc, Said Saim, Jay S Duker, Dario Paggiarino, Howard Sparks Michelle filed Critical Eyepoint Pharmaceuticals Inc
Publication of IL315331A publication Critical patent/IL315331A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL315331A 2022-03-11 2023-03-10 A method of preventing age-related ocular degeneration by providing a drug entry mechanism into the eye IL315331A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263318822P 2022-03-11 2022-03-11
US202263390036P 2022-07-18 2022-07-18
PCT/US2023/064139 WO2023173088A1 (en) 2022-03-11 2023-03-10 Method of preventing age-related macular degeneration by administering an ocular drug delivery insert

Publications (1)

Publication Number Publication Date
IL315331A true IL315331A (en) 2024-10-01

Family

ID=85873993

Family Applications (1)

Application Number Title Priority Date Filing Date
IL315331A IL315331A (en) 2022-03-11 2023-03-10 A method of preventing age-related ocular degeneration by providing a drug entry mechanism into the eye

Country Status (9)

Country Link
US (1) US20250205152A1 (https=)
EP (1) EP4489749A1 (https=)
JP (1) JP2025508127A (https=)
KR (1) KR20250002220A (https=)
AU (1) AU2023230975A1 (https=)
CA (1) CA3245205A1 (https=)
IL (1) IL315331A (https=)
TW (1) TW202345803A (https=)
WO (1) WO2023173088A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3886946A1 (en) 2019-06-05 2021-10-06 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2565683T3 (es) 2006-09-15 2016-04-06 Xcovery, Inc. Compuestos inhibidores de quinasa
WO2018059556A1 (zh) 2016-09-29 2018-04-05 贝达药业股份有限公司 激酶抑制剂化合物的多晶型、含其的药物组合物及其制备方法和应用
EP4537830A3 (en) * 2017-06-13 2025-06-11 EyePoint Pharmaceuticals, Inc. Bioerodible drug delivery devices
AU2021340733A1 (en) * 2020-09-14 2023-05-18 EyePoint Pharmaceuticals, Inc. Bioerodible ocular drug delivery insert and therapeutic method

Also Published As

Publication number Publication date
US20250205152A1 (en) 2025-06-26
WO2023173088A1 (en) 2023-09-14
CA3245205A1 (en) 2023-09-14
AU2023230975A1 (en) 2024-09-19
TW202345803A (zh) 2023-12-01
JP2025508127A (ja) 2025-03-21
EP4489749A1 (en) 2025-01-15
KR20250002220A (ko) 2025-01-07

Similar Documents

Publication Publication Date Title
IL315331A (en) A method of preventing age-related ocular degeneration by providing a drug entry mechanism into the eye
MX2023002902A (es) Inserto bioerosionable de administracion ocular de farmacos y metodo terapeutico.
Sallam et al. Repeat intravitreal triamcinolone acetonide injections in uveitic macular oedema
MX2019008963A (es) Composicion para la prevencion o el tratamiento de deterioros visuales que comprenden acido ursodesoxicolico.
MX349901B (es) Uso de un antagonista de factor de crecimiento endotelial vascular para tratar transtornos oculares angiogenicos.
ES3064888T3 (en) Apparatus for delivery of ocular implants
RU2014132553A (ru) Фармацевтическая композиция для уменьшения осложнений применения стероидных препаратов при лечении офтальмологических заболеваний
MD438Y (en) Method for treating hypermature senile cataract
MD437Y (en) Method for treating senile cataract
NZ749389A (en) Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement
AU2021354969A9 (en) METHODS OF TREATING AGE-RELATED MACULAR DISEASES USING AIMP2-DX2 AND OPTIONALLY A TARGET SEQUENCE FOR miR-142 AND COMPOSITIONS THEREOF
MD500Y (en) Device and method for treatment of hypermature senile cataract
WO2008048675A3 (en) Treatment for age-related macular degeneration and other diseases of the eye
JOP20240112A1 (ar) طريقة علاج الضمور الجغرافي باستخدام ناقل العلاج الجيني الذي يعبر عن cd59 القابل للذوبان
AU2022218993A9 (en) Methods for ophthalmic delivery of roflumilast
EP4138779A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION
EP4327806A4 (en) CAPSULE FOR SPECIFIC MEDICATION DELIVERY AND MANUFACTURING PROCESS THEREFOR
RU2012127869A (ru) Устойчивые водные композиции пролекарств агонистов простагладина и способы их применения
NZ594728A (en) Use of deferiprone for treatment and prevention of iron-related eye disorders
WO2006117666A3 (en) Dosage forms, pharmaceutical compositions and methods for sub-tenon delivery
Tsubura et al. N-Methyl-N-nitrosourea animal models for retinitis pigmentosa
CA3284565A1 (en) Methods for treatment of age-related macular degeneration
HK40096353A (en) Methods of treating age-related macular diseases using aimp2-dx2 and optionally a target sequence for mir-142 and compositions thereof
HK40095029A (en) Intraocular implant for drug delivery
CA3261060A1 (en) THERAPEUTIC COMPOSITIONS AND TREATMENT METHODS FOR AGE-RELATED MACULAR DEGENERATION